Applied Clinical Trials
Executives from Atlantic Research Group discuss the importance of CRAs in rare disease clinical trials.
Paul Bishop and Lyle Camblos
Advertisement
Paul Bishop is CEO, Atlantic Research Group (ARG), and can be reached at [email protected] Lyle Camblos is Managing Partner, Atlantic Research Group (ARG) and can be reached at [email protected]
Articles by Paul Bishop and Lyle Camblos
Advertisement
Latest Updated Articles
- The Value of Empowered CRAs in Rare Disease Studies
August 2nd 2017
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
The CRA of the Future: From Monitoring Activity to Strategic Site Partnership
2
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
3
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
4
Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad
5